BioPharmSignal logoBioPharmSignal

Biotech News

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

RenovoRx (RNXT)RenovoRxEarnings

RNXT (RNXT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is rnxt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

RNXTRenovoRx2026-07-29 12:30 EST

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

RNXTRenovoRx2026-08-12 20:05 EST

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

KURAKura Oncology2026-08-12 20:02 EST

Kura Oncology Reports Second Quarter 2026 Financial Results

ERASErasca2026-08-11 20:01 EST

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

View all latest news

RenovoRx

Targeted Intra-Arterial Drug Delivery RenovoRx develops a localized drug-delivery approach intended to concentrate therapy within solid tumors while reducing systemic exposure. Its Trans-Arterial Micro-Perfusion platform combines a device with a targeted treatment protocol. RenovoCath RenovoCath is an FDA-cleared dual-balloon infusion...

Recent company news

RNXTRenovoRx2026-08-21 12:30 EST

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

RNXTRenovoRx2026-08-20 12:30 EST

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

RNXTRenovoRx2026-08-12 20:05 EST

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

RNXTRenovoRx2026-08-11 12:30 EST

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RNXTRenovoRx2026-08-06 12:30 EST

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

Stock data

Close
1.32 USD
Market cap
41.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States